Previously a Managing Director, Kevin Wasserstein is now an Affiliated Director with Versant Ventures and represents Versant on the Autonomic Technologies, Cereve, Microfabrica, and ROX Medical Boards.
Before joining Versant in 2002, Kevin held a variety of marketing and business development roles at Guidant Corporation. Most recently he served as head of marketing in Guidant’s Cardiac Surgery Group, where he led the group’s product/market development and launch initiatives. In Guidant’s Peripheral and Carotid Group, Kevin developed and launched several first-generation stent and embolic protection devices while leading the carotid stent program’s marketing activities. Previously, in Guidant’s Compass Business Development Group, Kevin’s responsibilities included acquisition, licensing and investment with both private and public medical device companies, and corporate strategy. His operational experience also includes business development at Heartstream, and engineering design and engineering management at Hughes Aircraft Company.
Kevin holds both Bachelor’s and Master’s degrees in Mechanical Engineering, specializing in product design, as well as an MBA, all from Stanford University.
Current Versant Board Seats
Autonomic Technologies, Cereve, Microfabrica, ROX Medical
Previous Versant Board Involvement
Acclarent – observer (acquired), Cellutions, LipoSonix – observer (acquired), Lutonix (acquired), NDO Surgical (acquired), NeoGuide Systems – observer (acquired), Respicardia, St Francis Medical – observer (acquired), The Innovation Factory